Condition
Pancreatic Cancer, Advanced or Metastatic
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07528430Not Yet RecruitingPrimary
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
NCT07030257Phase 1Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT06783140Phase 2RecruitingPrimary
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
NCT00561990Phase 2CompletedPrimary
Nimotuzumab in Adults With Pancreatic Cancer
Showing all 4 trials